Vaskuläre Demenz

Christian Kluckert; Michael Hüll

doi:10.1055/a-1220-4197

PSYCH up2date, Table of Contents

PSYCH up2date 2021; 15(06): 467-486
DOI: 10.1055/a-1220-4197

Organische psychische Störungen

Vaskuläre Demenz

Christian Kluckert

¹Universitäre Altersmedizin Felix Platter, Basel, Schweiz

,

Michael Hüll

› Author Affiliations

Abstract

All articles of this category

Als vaskuläre Demenz bezeichnet man die Konstellation eines demenziellen Syndroms in Verbindung mit einer, als ursächlich angenommenen, vaskulären Hirnschädigung. Verlauf und Profil kognitiver Defizite sind je nach Art und Ort der Schädigung sehr variabel, Überschneidungen mit insbesondere einer zusätzlichen Alzheimer-Pathologie im Alter häufig. Neuere Diagnosekriterien berücksichtigen auch kognitive Störungen, die (noch) nicht die Kriterien einer Demenz erfüllen.

Schlüsselwörter

vaskuläre Demenz - Alzheimer-Demenz - Diagnostik - Therapie

Full Text

References

Literatur
1 Wolters FJ, Ikram MA. Epidemiology of Vascular Dementia. Arterioscler Thromb Vasc Biol 2019; 39: 1542-1549
2 Schneider JA, Arvanitakis Z, Bang W. et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69: 2197-2204
3 AWMF. S3-Leitlinie Demenzen. AWMF-Register-Nr. 038–013. 2016 https://www.awmf.org/leitlinien/detail/ll/038–013.html Stand: 22.08.2021
4 Hachinski V, Einhäupl K, Ganten D. et al. Preventing dementia by preventing stroke: The Berlin Manifesto. Alzheimers Dement 2019; 15: 961-984
5 Erkinjuntti T, Gauthier S. The concept of vascular cognitive impairment. Front Neurol Neurosci 2009; 24: 79-85
6 Skrobot OA, Black SE, Chen C. et al. Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. Alzheimers Dement 2018; 14: 280-292
7 Cannistraro RJ, Badi M, Eidelman BH. et al. CNS small vessel disease: A clinical review. Neurology 2019; 92: 1146-1156
8 Schmidt R, Berghold A, Jokinen H. et al. White matter lesion progression in LADIS: frequency, clinical effects, and sample size calculations. Stroke 2012; 43: 2643-2647
9 de Groot JC, de Leeuw FE, Oudkerk M. et al. Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann Neurol 2000; 47: 145-151
10 de Leeuw FE, de Groot JC, Achten E. et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry 2001; 70: 9-14
11 Jokinen H, Gouw AA, Madureira S. et al. Incident lacunes influence cognitive decline: the LADIS study. Neurology 2011; 76: 1872-1878
12 van Veluw SJ, Zwanenburg JJ, Rozemuller AJ. et al. The spectrum of MR detectable cortical microinfarcts: a classification study with 7-tesla postmortem MRI and histopathology. J Cereb Blood Flow Metab 2015; 35: 676-683
13 Arvanitakis Z, Leurgans SE, Barnes LL. et al. Microinfarct pathology, dementia, and cognitive systems. Stroke 2011; 42: 722-727
14 Maclullich AM, Wardlaw JM, Ferguson KJ. et al. Enlarged perivascular spaces are associated with cognitive function in healthy elderly men. J Neurol Neurosurg Psychiatry 2004; 75: 1519-1523
15 Chung CP, Chou KH, Chen WT. et al. Strictly Lobar Cerebral Microbleeds Are Associated With Cognitive Impairment. Stroke 2016; 47: 2497-2502
16 Akoudad S, Wolters FJ, Viswanathan A. et al. Association of Cerebral Microbleeds With Cognitive Decline and Dementia. JAMA Neurol 2016; 73: 934-943
17 Keage HA, Carare RO, Friedland RP. et al. Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review. BMC Neurol 2009; 9: 3
18 Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm (Vienna) 2002; 109: 813-836
19 Dichgans M, Leys D. Vascular Cognitive Impairment. Circ Res 2017; 120: 573-591
20 Hachinski VC, Lassen NA, Marshall J. Multi-infarct dementia. A cause of mental deterioration in the elderly. Lancet 1974; 2: 207-210
21 Moulin S, Labreuche J, Bombois S. et al. Dementia risk after spontaneous intracerebral haemorrhage: a prospective cohort study. Lancet Neurol 2016; 15: 820-829
22 Aam S, Einstad MS, Munthe-Kaas R. et al. Post-stroke Cognitive Impairment-Impact of Follow-Up Time and Stroke Subtype on Severity and Cognitive Profile: The Nor-COAST Study. Front Neurol 2020; 11: 699
23 Schneider JA, Arvanitakis Z, Bang W. et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69: 2197-2204
24 Ye BS, Seo SW, Kim JH. et al. Effects of amyloid and vascular markers on cognitive decline in subcortical vascular dementia. Neurology 2015; 85: 1687-1693
25 Heinen R, Groeneveld ON, Barkhof F. et al. Small vessel disease lesion type and brain atrophy: The role of co-occurring amyloid. Alzheimers Dement 2020; 12: e12060
26 Righart R, Duering M, Gonik M. et al. Impact of regional cortical and subcortical changes on processing speed in cerebral small vessel disease. Neuroimage Clin 2013; 2: 854-861
27 Looi JC, Sachdev PS. Differentiation of vascular dementia from AD on neuropsychological tests. Neurology 1999; 53: 670-678
28 Paolucci S. Epidemiology and treatment of post-stroke depression. Neuropsychiatr Dis Treat 2008; 4: 145-154
29 Stolze H, Vieregge P, Deuschl G. Gangstörungen in der Neurologie. Nervenarzt 2008; 79: 485-499
30 Jamour M, Becker C, Synofzik M. et al. Gangveränderungen als Frühindikator einer Demenz. Z Gerontol Geriat 2012; 45: 40-44
31 Zietemann V, Georgakis MK, Dondaine T. et al. Early MoCA predicts long-term cognitive and functional outcome and mortality after stroke. Neurology 2018; 91: e1838-e1850
32 Jorm A, Korten A. Assessment of Cognitive Decline in the Elderly by Informant Interview. Br J Psychiatry 1988; 152: 209-213
33 Lueken U, Seidl U, Schwarz M. et al. Die Apathy Evaluation Scale: Erste Ergebnisse zu den psychometrischen Eigenschaften einer deutschsprachigen Übersetzung der Skala. Fortschr Neurol Psychiatr 2006; 74: 714-722
34 Smith EE, Barber P, Field TS. et al. Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment. Alzheimers Dement (N Y) 2020; 6: e12056
35 Vernooij MW, Pizzini FB, Schmidt R. et al. Dementia imaging in clinical practice: a European-wide survey of 193 centres and conclusions by the ESNR working group. Neuroradiology 2019; 61: 633-642
36 Verhagen MV, Guit GL, Hafkamp GJ. et al. The impact of MRI combined with visual rating scales on the clinical diagnosis of dementia: a prospective study. Eur Radiol 2016; 26: 1716-1722
37 Hachinski V, Einhäupl K, Ganten D. et al. Preventing dementia by preventing stroke: The Berlin Manifesto. Alzheimers Dement 2019; 15: 961-984
38 Iadecola C, Duering M, Hachinski V. et al. Vascular Cognitive Impairment and Dementia: JACC Scientific Expert Panel. J Am Coll Cardiol 2019; 73: 3326-3344
39 Hughes D, Judge C, Murphy R. et al. Association of Blood Pressure Lowering With Incident Dementia or Cognitive Impairment: A Systematic Review and Meta-analysis. JAMA 2020; 323: 1934-1944
40 Ding J, Davis-Plourde KL, Sedaghat S. et al. Antihypertensive medications and risk for incident dementia and Alzheimer’s disease: a meta-analysis of individual participant data from prospective cohort studies. Lancet Neurol 2020; 19: 61-70
41 Aarsland D, Sardahaee FS, Anderssen S. et al. Is physical activity a potential preventive factor for vascular dementia? A systematic review. Aging Ment Health 2010; 14: 386-395
42 Klimova B, Dostalova R. The Impact of Physical Activities on Cognitive Performance among Healthy Older Individuals. Brain Sci 2020; 10: 377
43 Choi D, Choi S, Park SM. Effect of smoking cessation on the risk of dementia: a longitudinal study. Ann Clin Transl Neurol 2018; 5: 1192-1199
44 Rehm J, Hasan OSM, Black SE. et al. Alcohol use and dementia: a systematic scoping review. Alzheimers Res Ther 2019; 11: 1
45 Friberg L, Rosenqvist M. Less dementia with oral anticoagulation in atrial fibrillation. Eur Heart J 2018; 39: 453-460
46 Jin BR, Liu HY. Comparative efficacy and safety of cognitive enhancers for treating vascular cognitive impairment: systematic review and Bayesian network meta-analysis. Neural Regen Res 2019; 14: 805-816
47 Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007; 6: 782-792
48 Woods B, Aguirre E, Spector AE. et al. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database Syst Rev 2012; 2: CD005562
49 Piras F, Carbone E, Faggian S. et al. Efficacy of cognitive stimulation therapy for older adults with vascular dementia. Dement Neuropsychol 2017; 11: 434-441
50 Bahar-Fuchs A, Martyr A, Goh AM. et al. Cognitive training for people with mild to moderate dementia. Cochrane Database Syst Rev 2019; 3: CD013069
51 O' Philbin L, Woods B, Farrell EM. et al. Reminiscence therapy for dementia: an abridged Cochrane systematic review of the evidence from randomized controlled trials. Expert Rev Neurother 2018; 18: 715-727
52 Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc 2011; 59: 577-585
53 Rabins PV, Blacker D. APA Work Group on Alzheimer’s Disease and other Dementias. et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. Second edition. Am J Psychiatry 2007; 164 (Suppl. 12) 5-56
54 Burke AD, Goldfarb D, Bollam P. et al. Diagnosing and Treating Depression in Patients with Alzheimer's Disease. Neurol Ther 2019; 8: 325-350
55 Ruthirakuhan MT, Herrmann N, Abraham EH. et al. Pharmacological interventions for apathy in Alzheimer's disease. Cochrane Database Syst Rev 2018; 5: CD012197